- Home
- SMTK vs SNGX Comparison
SMTK vs SNGX Comparison
Compare SMTK & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- SNGX
- Stock Information
- Founded
- SMTK 2009
- SNGX 1987
- Country
- SMTK United Kingdom
- SNGX United States
- Employees
- SMTK N/A
- SNGX N/A
- Industry
- SMTK
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- SNGX Health Care
- Exchange
- SMTK NYSE
- SNGX Nasdaq
- Market Cap
- SMTK 6.1M
- SNGX 6.5M
- IPO Year
- SMTK N/A
- SNGX 1987
- Fundamental
- Price
- SMTK $0.97
- SNGX $1.28
- Analyst Decision
- SMTK
- SNGX
- Analyst Count
- SMTK 0
- SNGX 0
- Target Price
- SMTK N/A
- SNGX N/A
- AVG Volume (30 Days)
- SMTK 192.5K
- SNGX 2.7M
- Earning Date
- SMTK 08-11-2025
- SNGX 08-08-2025
- Dividend Yield
- SMTK N/A
- SNGX N/A
- EPS Growth
- SMTK N/A
- SNGX N/A
- EPS
- SMTK N/A
- SNGX N/A
- Revenue
- SMTK $105,000.00
- SNGX $2,342.00
- Revenue This Year
- SMTK N/A
- SNGX N/A
- Revenue Next Year
- SMTK N/A
- SNGX N/A
- P/E Ratio
- SMTK N/A
- SNGX N/A
- Revenue Growth
- SMTK 854.54
- SNGX N/A
- 52 Week Low
- SMTK $0.78
- SNGX $1.09
- 52 Week High
- SMTK $7.80
- SNGX $8.55
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- SNGX 34.55
- Support Level
- SMTK N/A
- SNGX $1.09
- Resistance Level
- SMTK N/A
- SNGX $1.88
- Average True Range (ATR)
- SMTK 0.00
- SNGX 0.14
- MACD
- SMTK 0.00
- SNGX -0.01
- Stochastic Oscillator
- SMTK 0.00
- SNGX 22.78
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in several applications, including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).